Page 85 - NobleCon21

GeoVax Labs, Inc.

SELECTED FINANCIAL ITEMS GOVX
(in millions of USD)
CQ4 '24 CQ1 '25 CQ2 '25 CQ3 '25 LTM
Income Statement Key Items
Total Revenue 0.86 1.64 0.85 NA 3.35
Gross Profit (6.74) (3.72) (3.88) (5.04) (19.38)
Gross Margin -780% -227% -455% NM -578%
EBIT (8.34) (5.41) (5.42) (6.37) (25.54)
EBIT Margin -965% -330% -636% NM -762%
Net Income to Common Shareholders (8.26) (5.36) (5.37) (6.32) (25.31)
Net Margin -956% -327% -630% NM -755%

Balance Sheet Key Items
Total Assets 8.16 10.83 5.35 6.73 6.73
Cash & Short Term Investments 5.51 7.44 3.09 5.01 5.01
% of Assets 68% 69% 58% 74% 74%
Current Assets -Total 7.93 10.61 5.14 6.52 6.52
% of Assets 97% 98% 96% 97% 97%
Total Liabilities 3.11 2.94 2.53 1.82 1.82
% of Assets 38% 27% 47% 27% 27%
Current Liabilities - Total 3.11 NA 2.53 1.82 1.82
% of Assets 38% NM 47% 27% 27%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 5.05 7.90 2.82 4.91 4.91
% of Assets 62% 73% 53% 73% 73%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (7.75) NA NA (6.21) (13.97)
Net Cash Flow - Investing 0.00 NA NA 0.00 0.00
Net Cash Flow - Financing 4.67 NA NA 8.13 12.80

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference